Van Criekinge
Wim Van Criekinge, Waarloos BE
Patent application number | Description | Published |
---|---|---|
20100280134 | Markers for Bladder Cancer Detection - A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The gene may be TWIST1 or a panel of genes such as TWIST1, NID2 and RUNX3 may be screened. The epigenetic change may be methylation. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises at least one primer pair for determining the methylation status of each of NID2, TWIST1 and RUNX3. A kit for detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises means for detecting an epigenetic change in at least one gene selected from TWIST1, NID2, RUNX3, BMP7, CCNA1, PDLIM4, TNFRSF25, APC, RASSF1A, LOXL1, TUBB4, NTRK2, ARFGAP3, OSMR and TJP2. The kit also contains means for processing a urine sample. | 11-04-2010 |
20140089009 | Method for Personal Genome Data Management - A method for personal genome information management includes receiving personal genome sequence data at a mobile device. The personal genome sequence data is compared to a reference genome sequence data to identify one or more sequence variants from the personal genome sequence data. One or more sequence variants from the personal genome sequence data are assigned to categories of hierarchical lists. One or more visual displays are provided to the user based upon the assignment of the sequence variants in the categories of hierarchical lists. | 03-27-2014 |
20140322714 | Methods of Detecting Mutations and Epigenetic Changes - Disclosed are methods for assessing the methylation and mutation status of nucleic acid in a sample. The methods provide for methylation-dependent modification of the nucleic acid in a sample, and subsequently nucleic acid amplification processes to distinguish between mutated and non-mutated target sequence. | 10-30-2014 |
Wim Van Criekinge, Sart-Tilman (liege) BE
Patent application number | Description | Published |
---|---|---|
20080221056 | Early Detection and Prognosis of Colon Cancers - We have developed a transcriptome-wide approach to identify genes affected by promoter CpG island hypermethylation and transcriptional silencing in colorectal cancer (CRC). By screening cell lines and validating tumor specific hypermethylation in a panel of primary human CRC samples, we estimate that nearly 5% of all known genes may be promoter methylated in an individual tumor. When directly compared to gene mutations, we find a much larger number of genes hypermethylated in individual tumors, and much higher frequency of hypermethylation within individual genes harboring either genetic or epigenetic changes. Thus, to enumerate the full spectrum of alterations in the human cancer genome, and facilitate the most efficacious grouping of tumors to identify cancer biomarkers and tailor therapeutic approaches, both genetic and epigenetic screens should be undertaken. The genes we identified can be used inter alia diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer. | 09-11-2008 |
20090203639 | Methylation Markers for Diagnoses and Treatment of Cancers - Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments. | 08-13-2009 |
20090215709 | Methylation markers for diagnosis and treatment of cancers - Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments. | 08-27-2009 |
20100035970 | Methylation Markers for Diagnosis and Treatment of Cancers - Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments. | 02-11-2010 |
Wim Van Criekinge, Sart-Tilman BE
Patent application number | Description | Published |
---|---|---|
20110117551 | DETECTION AND PROGNOSIS OF LUNG CANCER - Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655. | 05-19-2011 |
20110189653 | DETECTION AND PROGNOSIS OF CERVICAL CANCER - The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof. | 08-04-2011 |
20150017634 | Detection and Prognosis of Cervical Cancer - The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof. | 01-15-2015 |
Wim Van Criekinge, Leuven BE
Patent application number | Description | Published |
---|---|---|
20120196827 | METHYLATION MARKERS FOR EARLY DETECTION AND PROGNOSIS OF COLON CANCERS - Using a combination of analytic methods epigenetic silencing of markers in cancer have been determined. The cancers are generally those of the gastrointestinal tract including but not limited to esophageal, head and neck, gastric, pancreas, liver, and colon. The genes can be used for the early detection of cancer or can be used to identify adenomas that will likely progress to carcinomas. Therapeutic regimens based on the epigenetic silenced genes can be chosen and/or monitored. Kits for evaluating epigenetic silencing of these genes can be used for detection and monitoring. | 08-02-2012 |
Wim Wim Van Criekinge, Sart-Tilman (liege) BE
Patent application number | Description | Published |
---|---|---|
20090011049 | Methylation Markers for Prognosis and Treatment of Cancers - Genes for thirteen DNA damage repair or DNA damage response enzymes can be epigenetically silenced in cancers. The silencing of nucleic acids encoding a DNA repair or DNA damage response enzyme can be used prognostically and for selecting treatments that are well tailored for an individual patient. Combinations of these markers can also be used to provide prognostic information. Kits for testing epigenetic silencing can be used to determine a prognosis or a therapeutic regimen. | 01-08-2009 |